Tag: ILMN

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

[1/2] A sign at the front entrance to the global headquarters of Illumina is pictured in San Diego, California, U.S., November 28, 2022. REUTERS/Mike Blake/File Photo WASHINGTON, June 5 (Reuters) – Life sciences firm Illumina (ILMN.O) on Monday filed an appeal against a Federal Trade Commission (FTC) order demanding that…

SAN DIEGO, June 5, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report, highlighting the company’s commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022….

Illumina, Inc. ILMN recently unveiled new PrimateAI-3D — an artificial intelligence (AI) algorithm which identifies disease-causing genetic mutations in patients. PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software. The National Institutes of Health estimate that the annual production of genomic data is reaching…

Hologic CEO Stephen MacMillan Illumina (NASDAQ: ILMN) announced today that its board has elected Hologic CEO Stephan MacMillan to fill a new seat and become its non-executive chair. Edwards Lifesciences CFO Scott Ullem will fill a second new seat — bringing the number of board seats to 11 at the…

Illumina, Inc. (NASDAQ: ILMN) launched PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts disease-causing genetic mutations in patients. PrimateAI-3D utilizes deep neural network architectures similar to ChatGPT and AlphaFold, but is trained on genome sequences rather than human language. After applying the algorithm to half a million genomes in the U.K. Biobank…

  Stephen P. MacMillan, Hologic CEO, named non-executive Chair of Illumina’s Board Scott B. Ullem, CFO of Edwards Lifesciences, also named to Board SAN DIEGO, June 2, 2023 /PRNewswire/ —Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced…

Published findings demonstrate PrimateAI-3D’s ability to improve genetic risk prediction and drug target discovery using primate DNA and advanced artificial intelligence SAN DIEGO, June 1, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI)…

Data also shows that current standard-of-care testing for cancer patients falls short in multiple ways SAN DIEGO, May 30, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP)…

Earlier this month we dissected the ongoing battle between investor activist Carl Icahn and the second-biggest holding in our Nanalyze Disruptive Tech Portfolio – Illumina (ILMN). The latest round just came to an end on May 25 when shareholders approved one of Icahn’s three hand-picked nominees for the gene-sequencing company’s…

Shareholders of the world’s largest gene sequencing company Illumina, (NASDAQ:ILMN), have proven their disapproval of the board’s past decisions by ousting Chairman John Thompson at the annual shareholder meeting yesterday. Instead, they voted in favor of activist investor Carl Icahn’s nominee, Andrew Teno, marking a first-of-its-kind victory for activism at…

Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO, May 25, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina…

Illumina shareholders re-elect eight of nine Illumina directors SAN DIEGO, May 25, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that based on the preliminary results of its 2023 Annual Meeting, Illumina shareholders have voted to elect eight of nine Illumina…

The biotech company Illumina has become a battleground between big business and big government. In the coming months, courts in the U.S. and Europe will rule whether Illumina (ticker: ILMN) must abandon its $8 billion acquisition of the cancer-testing company Grail, under orders of antitrust authorities. Illumina argues that it’s…

Baron Funds, an investment management company, released its “Baron Partners Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. Despite the market volatility, the fund performed well and returned 23.41% in the first quarter, which exceeds the Russell Midcap Growth Index’s 9.14% return and the…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

Carl Icahn (Trades, Portfolio) is one of the most iconic activist investors or “corporate raiders” that has ever existed. Despite being 87 years old, he is still very active in the market. His latest target is Illumina Inc. (ILMN, Financial), a genomics company which he recently launched a proxy battle…

Board Chair John Thompson issues letter to Illumina shareholders ahead of the company’s Annual Meeting on May 25, 2023 , at 10:00 am Pacific Time ( 1:00 pm Eastern Time ) Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina’s director nominees For more…

Carl Icahn, one of Wall Street’s fiercest activists, is taking a big swipe next week, as he attempts to unseat the brash CEO of Illumina, the dominant player in the field of gene sequencing. Illumina ’s (ticker: ILMN) sequencing machines are behind scientific advances already changing science and medicine. The…

Illumina’s director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBC Leading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein Icahn’s associates bring ZERO relevant experience and ZERO independence Illumina requests shareholders…

Dive Brief: Illumina shareholders should withhold support for board chair John Thompson and back activist investor Carl Icahn’s nominee Andrew Teno for a seat on the board, proxy advisory firm Institutional Shareholder Services said on May 12. Illumina defended Thompson in a response to the ISS report, saying his deep…

Illumina’s director nominees bring deep commercial, scientific and business experience from leading organizations including Microsoft, Symantec, and Medco-UBC Leading proxy advisory firm ISS has recommended Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein Icahn’s associates bring ZERO relevant experience and ZERO independence Illumina requests shareholders…

SAN DIEGO, May 12, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein….

SAN DIEGO, May 12, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy voting and corporate governance advisory firm, recommends Illumina shareholders vote FOR Illumina CEO Francis deSouza and Board member Robert Epstein….

  Illumina is led by its world-class Board members and has best-in-class governance practices Carl Icahn’s recently released “plan” demonstrates his lack of understanding of both Illumina and the genomics industry Illumina requests shareholders to vote the WHITE proxy card today FOR all nine…

Illumina is led by its world-class Board members and has best-in-class governance practices Carl Icahn’s recently released “plan” demonstrates his lack of understanding of both Illumina and the genomics industry Illumina requests shareholders to vote the WHITE proxy card today FOR all nine of Illumina’s director nominees Annual Meeting will…

Illumina (ILMN 1.71%) and Bionano Genomics (BNGO 9.95%) might both make gene sequencing devices, but as investments the two couldn’t be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is…

Preparation of total transcriptome libraries for sequencing on an Illumina dais Edit me Documentation TruSeq Running Absolute RNA Sample Prep Guide. This method makes a cDNA library of all RNA molecules presentational in your spot after rRNA depletion. Important: the succeed of this kit is dependent on of ability of…

The phrase, “I’m from the government and I’m here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. NASDAQ: ILMN, which specializes in DNA sequencing, government meddling could actually end up helping shareholders.  That “help” could manifest itself if regulators force a divesture…

With the labor market expanding and inflation receding, it’s time to identify breakout growth stocks with significant potential. As the U.S. economy continues to defy the odds with its resiliency, it’s arguably an ideal time for investors to seek the best breakout stocks for an explosive rally ahead. The recent…

The Future Is Bright genomic literacy initiative expands to Japan, South Korea and United Arab Emirates SAN DIEGO, May 2, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced outcomes from its annual The Future Is Bright campaign, a monthlong global…

Strong NovaSeqTM X shipments drove solid Illumina first quarter results; company commits to grow Core Illumina non-GAAP operating margins to 27%[1] in 2025 Announces more than $100 million in annualized cost savings Carl Icahn’s campaign is spreading false information Carl Icahn’s unqualified nominees are potentially harmful to Illumina’s core business, if elected…

On May 1, 2023, Illumina, a leading global company in DNA sequencing and array-based technologies, released a shareholder letter calling for the support of all nine of Illumina’s director nominees on the WHITE proxy card at the upcoming Annual Meeting. The virtual meeting will occur on May 25, 2023, at…

Strong NovaSeqTM X shipments drove solid Illumina first quarter results; company commits to grow Core Illumina non-GAAP operating margins to 27%[1] in 2025 Announces more than $100 million in annualized cost savings Carl Icahn’s campaign is spreading false information Carl Icahn’s unqualified nominees are potentially harmful to Illumina’s core business,…

The NASDAQ: ILMN opened on Friday, April 29, 2023, at $204.39 with a market capitalization of $32.30 billion. Illumina has had a successful year with an all-time high of $309.12 and a low of $173.45 in the last 12 months. The company has a P/E ratio of -7.16, a PEG…

The FDA issued a letter noting that nearly the entire Illumina Inc’s (NASDAQ: ILMN) sequencer lineup carries a cybersecurity vulnerability that could impact genomic data results or even result in a data breach. The agency said that the Universal Copy Service software in the Illumina NovaSeq 6000, NextSeq 500, NextSeq 550, NextSeq 550Dx NextSeq…

Health care stocks were advancing Friday afternoon, with the NYSE Health Care Index climbing 1% and the Health Care Select Sector SPDR Fund (XLV) up 1.1%. The iShares Biotechnology ETF (IBB) was 1.5% higher. In company news, Bright Health Group (BHG) was shedding 1.5% after saying it’s exploring a potential…

As of April 27, 2023, the U.S. Food and Drug Administration (FDA) has issued a warning regarding a cybersecurity vulnerability discovered in Illumina’s Universal Copy Service software. This vulnerability can potentially pose risks to patient health results and customer networks. Fortunately, the FDA has not received any reports indicating the…

Illumina Inc. ILMN reported adjusted earnings per share (EPS) of 8 cents in the first quarter of 2023, sailing past the Zacks Consensus Estimate of 2 cents by a remarkable margin. However, the bottom line declined 92.5% from the year-ago quarter’s earnings of $1.07. The adjustments exclude the impact of GRAIL…

SAN DIEGO – Illumina, Inc. (Nasdaq: ILMN) (‘Illumina’ or the ‘company’) today announced its financial results for the first quarter of fiscal year 2023, which include the consolidated financial results for GRAIL. ‘The year is off to a solid start, led by NovaSeq X outperforming expectations in both customer demand…

Illumina: A Company Review Illumina Inc. (NASDAQ: ILMN) is a life sciences company that specializes in sequencing technologies and genomics solutions. The company provides innovative tools for scientific discovery, personalized medicine, agricultural research, and forensics. Established in 1998, the San Diego-based biotech firm has since expanded its operations globally and…

Year Long Programme with Science Centre Singapore to kick off on World DNA Day as part of Illumina’s Future is Bright Initiative. SINGAPORE, April 25, 2023 /PRNewswire/ — Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) today announced an inaugural partnership with the Science Centre Board to inspire 2,800 students through…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

illuminaHumanv2.db returning NA for all Illumina probe ID to gene symbol conversion 0 I have downloaded a miRNA expression dataset from NCBI GEO (GSE25631) to study differential gene expression and perform other analyses. As mentioned in GEO, this profiling was performed on GPL8179 Illumina Human v2 MicroRNA expression beadchip. Accordingly,…

This question was also asked on Biostars I am trying to download and analyze a miRNA expression dataset from NCBI GEO (GSE25631). I specifically want non-normalized data to perform normalization and my own set of other analyses later on. Accordingly, I downloaded the Series Matrix File (to match the Sample…

Edit November 28, 2020: Further reproducible code: A: GPL6883_HumanRef-8_V3_0_R0_11282963_A (illumina expression beadchip) — Most Illumina ‘chip’ studies that I have seen on GEO do not contain the raw data IDAT files. You can start with the tab-delimited file, but will also require the annotation file (contained in the *_RAW.tar file),…

SAN DIEGO, April 20, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today urged shareholders to vote in favor of Illumina’s slate of highly qualified director nominees. It also announced that its Annual Meeting will be held virtually on May 25, 2023, at…

I am trying to download and analyze a miRNA expression dataset from NCBI GEO (GSE25631). I specifically want non-normalized data to perform normalization and my own set of other analyses later on. Accordingly, I downloaded the Series Matrix File (to match the Sample IDs with their phenotype) and the non-normalized…

Carl Icahn didn’t mince words in his presentation opposing DNA sequencing giant Illumina’s (NYSE: ILMN) quest to own Grail — calling the actions an “existential question” for the company, Claire writes. Driving the news: The FTC on Monday rejected the deal, saying it will “stifle competition and innovation in the…

Series of studies will focus on genetic drivers of cardiovascular disease, and how data can improve care, especially in underserved communities SAN DIEGO, April 11, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Henry Ford Health, a not-for-profit health care organization…

Illumina, Inc. ILMN recently collaborated with African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) to develop a training academy. The collaboration is intended to increase Africa’s genomics capacity. The collaboration is built on the organizations’ shared goals to expand sequencing capabilities and capacity for all people in Africa….

Rafael Henrique | Lightrocket | Getty Images Illumina on Thursday urged shareholders to reject Carl Icahn‘s three board nominees at this year’s annual meeting, saying they would “threaten the progress” of the biotech company’s core business.  “Carl Icahn’s involvement with Illumina risks the long-term success of the Company, and his…

SAN DIEGO, March 30, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today filed its preliminary proxy statement with the Securities and Exchange Commission, which contains important information for shareholders. The activist investor Carl Icahn has nominated three of his associates to stand…

SAN DIEGO, March 24, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter from Carl Icahn dated March 24, 2023: Directors and Officers (D&O) insurance and corporate indemnification are standard for Delaware companies, and…

Solskin Thesis Oxford Nanopore Technologies plc (OTCPK:ONTTF) creates the technology required for studying and analyzing molecules. DNA sequencing, medical diagnosis, and drug discovery are just some of the applications for these innovations. When considering ONTFF as a stock, I find its long-term growth story appealing, and its current valuation (6x…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

Illumina’s plan will maximize shareholder value Illumina is engaged with regulators to define GRAIL’s path forward as expeditiously as possible Icahn’s director nominees do not add value to the Board and will damage Illumina’s core business SAN DIEGO, March 20, 2023 /PRNewswire/ — Illumina (NASDAQ: ILMN), a global leader in…

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy’ rating for Illumina Inc (NASDAQ:ILMN) following recent activism efforts against the biotechnology company led by veteran activist investor Carl Icahn. Icahn, who owns a 1.4% stake in the San Diego-based DNA sequencing company, on March 13 issued a letter to…

Illumina, Inc. ILMN recently launched its first product based on its novel Illumina Complete Long Read technology. The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina Complete Long Read is well-suited with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. More on the News Illumina’s Complete…

Illumina, Inc. (ILMN Quick QuoteILMN – Free Report) recently launched its first product based on its novel Illumina Complete Long Read technology. The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina Complete Long Read is well-suited with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems. More…

Gio_tto/iStock via Getty Images Illumina (NASDAQ:ILMN) should spin off Grail as regulators in European Union have moved to block the acquisition, billionaire activist Carl Icahn said. Icahn, who announced on Monday that he’s starting a proxy battle with gene-sequencing company, said Illumina (ILMN) needs to spin off Grail because the…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

Developing affordable therapies based on the products of next-generation gene sequencing requires a lot more work on four main areas, says Amati Global Investors. The four areas are cost, data, analysis and patient access, argues Dr Gareth Blades, an analyst on the fund management team. “There is a vision emerging in the industry…

Text size An Illumina competitor with a less-expensive price point unveiled new technology at a recent genome biology conference. Dreamstime Genetic information is driving most of today’s medical breakthroughs, and the industry that develops genetic decoders had its annual gathering last week. The most interesting news at the Advances in…

InvestorPlace – Stock Market News, Stock Advice & Trading Tips When looking for stocks to buy and hold for the next 20 years, it’s essential to find ones with economic moat. After all, when it comes to picking stocks, they should strong competitive advantages that are in durable sectors. Some…

New data on NovaSeq X Plus and workflow insights on Illumina Complete Long Reads unveiled at AGBT HOLLYWOOD, Fla., Feb. 8, 2023 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to…

Text size A technician handles an Illumina Advantage High Output Reagent Cartridge. T. Narayan/Bloomberg Illumina got to a $34 billion market cap and 140-times earnings multiple by dominating the fast-growing market for reading genes. The success of San Diego-based DNA sequencer’s Illumina (ticker: ILMN) and rich stock are naturally attracting…

piola666/E+ via Getty Images Investment Thesis Gene sequencing revolutionized our understanding of the human genome and its function. Today, we can accurately identify thousands of genetic variations that contribute to human health and disease, opening up the possibility of personalized medicine – creating medicine that is customized to the individual….

SAN DIEGO, Feb. 1, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately. Goswami previously served as Illumina’s Chief Strategy and Corporate Development Officer and interim Chief Financial Officer. As CFO,…

SAN DIEGO, Feb. 1, 2023 SAN DIEGO, Feb. 1, 2023 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami has been appointed Chief Financial Officer, effective immediately. Goswami previously served as Illumina’s Chief Strategy and Corporate Development Officer and interim…

QIAGEN NV (NYSE: QGEN) has acquired Verogen, a privately held company founded in 2017 and based in San Diego, for $150 million. QIAGEN expects about $20 million of sales from the Verogen portfolio in 2023, building on about $5 million for QIAGEN in 2022 from the distribution agreement. The transaction is expected to…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

Job Description GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation…

In an unusual step, the European Commission plans to intervene in the recent merger between Illumina (ILMN) and Grail because regulators were unable to finish reviewing the deal before it was completed, raising concerns that competition in the market for DNA sequencing tests will now be damaged. The move comes…

The high voltage drama surrounding the Illumina ILMN-Grail consolidation is showing no signs of drawing to a close. Following the completion of this longstanding and highly-disputed $7.1 billion merger last week without regulatory approvals, investors are currently waiting to see the magnitude of penalty that the European Commission (EC) might…